DDInter1008 DDInter143
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require platelet transfusions before surgical procedures to decrease the risk of bleeding. Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. It is administered orally as the salt form avatrombopag maleate. _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by increasing platelet counts to the optimal level ≥50,000 per microliter.
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Voriconazole
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Fosphenytoin
Fosphenytoin {u} may lead to a major life threatening interaction when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) causes {v} (Side Effect) Arthralgia
Arthralgia {u} (Side Effect) is caused by {v} (Compound) Voriconazole
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Avatrombopag
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Ketoconazole (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Ketoconazole (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Fosphenytoin (Compound) and Fosphenytoin may lead to a major life threatening interaction when taken with Avatrombopag
Ketoconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Avatrombopag
Ketoconazole (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Avatrombopag